CENTESSA PHARMACEUTICALS (260) - Total Liabilities
Based on the latest financial reports, CENTESSA PHARMACEUTICALS (260) has total liabilities worth €154.41 Million EUR (≈ $180.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 260 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
CENTESSA PHARMACEUTICALS - Total Liabilities Trend (2021–2025)
This chart illustrates how CENTESSA PHARMACEUTICALS's total liabilities have evolved over time, based on quarterly financial data. Check 260 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
CENTESSA PHARMACEUTICALS Competitors by Total Liabilities
The table below lists competitors of CENTESSA PHARMACEUTICALS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kanzhun Ltd ADR
NASDAQ:BZ
|
USA | $4.49 Billion |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
USA | $3.05 Billion |
|
GXO Logistics Inc
NYSE:GXO
|
USA | $9.35 Billion |
|
Cirrus Logic Inc
NASDAQ:CRUS
|
USA | $371.15 Million |
|
D-Wave Quantum Inc.
NYSE:QBTS
|
USA | $75.56 Million |
|
Joby Aviation
NYSE:JOBY
|
USA | $969.94 Million |
|
Colgate Palmolive (India) Limited
NSE:COLPAL
|
India | Rs-16.64 Billion |
|
SBM Offshore N.V.
AS:SBMO
|
Netherlands | €10.11 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down CENTESSA PHARMACEUTICALS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CENTESSA PHARMACEUTICALS total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CENTESSA PHARMACEUTICALS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CENTESSA PHARMACEUTICALS (2021–2025)
The table below shows the annual total liabilities of CENTESSA PHARMACEUTICALS from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €160.63 Million ≈ $187.80 Million |
-8.34% |
| 2024-12-31 | €175.25 Million ≈ $204.89 Million |
+41.33% |
| 2023-12-31 | €124.00 Million ≈ $144.97 Million |
+14.67% |
| 2022-12-31 | €108.14 Million ≈ $126.42 Million |
-21.69% |
| 2021-12-31 | €138.08 Million ≈ $161.43 Million |
-- |
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more